Pancreatic lipomatosis duodenal stenosis

disease
On this page

Also known as pancreatic lipomatosis and duodenal atresia

Summary

Pancreatic lipomatosis duodenal stenosis (MONDO:0043166) is a disease. A subtype of duodenal obstruction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepancreatic lipomatosis duodenal stenosis
Mondo IDMONDO:0043166
MeSHC535839
UMLSC2931040
MedGen419702
Is cancer (heuristic)no

Also known as: pancreatic lipomatosis and duodenal atresia

Disease family

This is a subtype of duodenal obstruction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderintestinal disorder › small intestine disorder › duodenal disorderduodenal obstructionpancreatic lipomatosis duodenal stenosis

Related subtypes (2): chronic duodenal ileus, superior mesenteric artery syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.